Vicore Pharma Holding AB

Vicore Pharma Holding AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Vicore Pharma and HealthCap create a leading drug development company focused on severe lung diseases

Tue, Jul 03, 2018 08:30 CET

Vicore Pharma Holding AB (publ) ("Vicore" or "The Company") has entered into an agreement to acquire INIM Pharma AB ("INIM"), a Swedish biopharmaceutical company developing a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis ("IPF"). Payment for the acquisition is effectuated through an issue in kind, corresponding to a dilution of 35.8 percent. HealthCap VII LP ("HealthCap") currently owns 85 percent of INIM and will hold approximately 30.4 percent of the shares in Vicore following the transaction. The Board of Directors of Vicore has decided to

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Vicore Pharma and HealthCap create a leading drug development company focused on severe lung diseases

Media